Affective biases and their interaction with other reward-related deficits in 1 rodent models of psychiatric disorders by Lewis, Lucy R et al.
1 
 
Affective biases and their interaction with other reward-related deficits in 1 
rodent models of psychiatric disorders  2 
Lucy R. Lewisa, Abigail Bennc, Dominic M. Dwyera, Emma S. J. Robinsonb*. 3 
aSchool of Psychology, Tower Building, Cardiff University, Park Place, Cardiff, United 4 
Kingdom, CF10 3AT. 5 
bSchool of Physiology, Pharmacology & Neuroscience, Biomedical Sciences Building, 6 
University of Bristol, University Walk, Bristol, United Kingdom, BS8 1TD. 7 
cUniversity of Oxford, Department of Experimental Psychology, Tinsley Building, Marsden 8 
Road, Oxford, OX1 3TA 9 
lewislr@cardiff.ac.uk 10 
Abigail.benn@psy.ox.ac.uk 11 
dwyerdm@cardiff.ac.uk 12 
emma.s.j.robinson@bristol.ac.uk *corresponding author. 13 
Abstract 14 
Major depressive disorder (MDD) is one of the leading global causes of disability. Symptoms 15 
of MDD can vary person to person, and current treatments often fail to alleviate the poor 16 
quality of life that patients experience. One of the two, core diagnostic criteria for MDD is the 17 
loss of interest in previously pleasurable activities, which suggests a link between the disease 18 
aetiology and reward processing. Cognitive impairments are also common in patients with 19 
MDD, and more recently, emotional processing deficits known as affective biases have been 20 
recognised as a key feature of the disorder. Studies in animals have found similar affective 21 
biases related to reward.  In this review we consider these affective biases in the context of 22 
other reward-related deficits and examine how affective biases associated with learning and 23 
memory may interact with the wider behavioural symptoms seen in MDD. We discuss recent 24 
developments in how analogues of affective biases and other aspects of reward processing 25 
can be assessed in rodents, as well as how these behaviours are influenced in models of MDD. 26 
We subsequently discuss evidence for the neurobiological mechanisms contributing to one 27 
or more reward-related deficits in preclinical models of MDD, identified using these 28 
behavioural assays. We consider how the relationships between these selective behavioural 29 
assays and the neurobiological mechanisms for affective bias and reward processing could be 30 
used to identify potential treatment strategies.  31 
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1. Introduction 34 
Depression is currently the leading global cause of disability [1]. According to the DSM-5, 35 
clinical depression or major depressive disorder (MDD) is a serious mood disorder 36 
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characterised by the presence of several symptoms including low mood, diminished interest 37 
or pleasure in almost all activities, slowness of thought processes/physical movements, and a 38 
diminished ability to think or concentrate [2]. 39 
This latter symptom may relate to two types of cognitive dysfunction experienced by patients 40 
with MDD, affective biases and cognitive deficits [3]. In this review, we focus on affective 41 
biases, which refer to how emotional or ‘affective’ states alter different cognitive processes. 42 
These biases can influence multiple cognitive domains including learning, memory and 43 
decision-making [4]. Affective biases have also been linked to the development of other 44 
symptoms of the disorder, suggesting some inter-relationship between negative affective 45 
biases and depressed mood, amotivation, anhedonia etc. [5]. It has been suggested that 46 
cognitive impairments that do not directly involve emotional/affective stimuli could still be 47 
linked to affective biases, for example, greater sensitivity to negative feedback from cognitive 48 
tasks or reduced positive associations during cognitive tasks involving rewards could lead to 49 
changes in goal-directed behaviour and motivation to perform the task [4].  50 
Although descriptive accounts and more formal diagnoses of depression have been made for 51 
some centuries [6], it is only more recently that the idea of heterogeneity in depressed 52 
populations has been addressed. An individual patient can have a number of symptoms but 53 
not share a single one with another patient, even though they are diagnosed with the same 54 
disorder [7]. Despite this, treatments are not personalised to match the symptoms present in 55 
each patient, partly because we do not yet have a full understanding of the neurobiology 56 
underlying symptoms individually. Differences in the neurobiology of components in reward 57 
processing are becoming increasingly recognised [8], some of which can match to symptoms 58 
seen in MDD patients, and MDD can be seen as a disorder of reward processing [9]. Thus, in 59 
order to understand the neurobiological mechanisms of this complex disorder, we need to 60 
analyse the individual reward-related symptoms of MDD, for which reliable animal models 61 
and translational behavioural assays are essential. Recent developments to back translate the 62 
ideas of affective biases in MDD to rodent studies has revealed biases in rodents related to 63 
reward-related learning, memory and decision-making [10].  This work suggests that biases in 64 
reward-related behaviour may be relevant to the wider symptoms of anhedonia in MDD. 65 
Current animal models of depression appear to demonstrate face validity in relation to 66 
behaviours comparable to distinct symptomology defined by the DSM criteria of MDD, 67 
including impairments following exposure to chronic stress, a major risk factor for depression 68 
[11, 12]. Whilst these behavioural assays (discussed in section 3) show good validity in terms 69 
of stress-induced behavioural deficits and are sensitive to some antidepressant treatments, 70 
how well they recapitulate the human condition, and hence can demonstrate translational 71 
validity, has been questioned [10, 13]. Recently, the idea that affective biases can be modelled 72 
in animals and provide a more translational approach to studying MDD in non-human species 73 
has emerged. The nature of the animal experiments has meant that such behaviours are often 74 
seen as biases in processing of reward-related stimuli, which has led us to consider the wider 75 
deficits in MDD, particularly anhedonia and the loss of motivation for previously rewarding 76 
activities [9, 14, 15].  77 
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Reliable behavioural assays in animal models can help to parse the underlying neurobiological 78 
mechanisms of these deficits, as well as how they interact, and provide clear targets for 79 
treating individual symptoms [8]. Traditional behavioural assays have focused on symptoms 80 
of behavioural despair/learned helplessness, in which MDD patients are conditioned to 81 
experience negative events such that they give up trying to escape such situations [16]. In 82 
rodents, this is often measured with the forced swim test (FST) for both mice and rats, or the 83 
tail suspension test (TST) for mice. Inescapable shock is also described as a method to induce 84 
learned helplessness [17] and has been used to induce a depression-like phenotype in animals 85 
with evidence for both vulnerable and resilient populations [18, 19]. In the FST, rodents are 86 
placed into an open container of water for a short period of time and their behaviour is 87 
recorded [20]. The animal swims around the container and attempts to escape, but eventually 88 
they stop moving and stay immobile. The time taken for the animal to become immobile can 89 
be used to measure this theory of learned helplessness. Pharmacological studies with pro- 90 
and anti-depressants have helped to validate this assay, with immobility time reducing with 91 
pro-depressants such as stressors, and increasing with typical antidepressants (see [21, 22] 92 
for a full review). The TST works on a similar principle, where mice are suspended by their tail 93 
so cannot escape. Immobility time is again used as a marker of learned helplessness [23].  94 
Although widely used in both fundamental biology research and drug development, the 95 
validity of these methods has been questioned, particularly given evidence of a number of 96 
false positive and false negative findings [23-25], and a lack of sensitivity to atypical 97 
antidepressants [26]. Impairments in immobility time is observed in some, but not all, disease 98 
models where risk factors for MDD have been used (for a full review of animal models of 99 
depression, see [27]). For example, the FST and TST are generally sensitive to stress-related 100 
manipulations, but deficits are not reliably observed in immunomodulatory or early life 101 
adversity interventions [28-31]. Recent arguments against the validity of such measurements 102 
include suggestions of anthropomorphising natural rodent survival and adaptation 103 
mechanisms [29], as well as the possibility of changes in motor function underlying these 104 
behaviours [32]. Although these methods are some of the most commonly used to measure 105 
depressive phenotypes and can, in some cases, be used to screen novel psychotropic drugs, 106 
they cannot be said to accurately model ‘depressive phenotypes’ that would be seen in 107 
patients (for detailed reviews see [33, 34]).   108 
This review will focus on direct assays of reward-related deficits which can be translated to 109 
symptoms often seen across patients with MDD. As anhedonia, the reduced ability to 110 
experience pleasure, is a core symptom of MDD, the most commonly used assay of reward-111 
related deficits in rodents aims to model this symptom in the sucrose preference test (SPT), 112 
in which overall consumption of a rewarding solution containing sucrose in comparison to 113 
plain water is measured as a choice test [35]. This method has been used for decades as one 114 
of the go-to measurement of depressive-like behaviours and reduced sucrose preference has 115 
commonly been assumed to indicate consummatory anhedonia [12, 36]. However, it is 116 
important to note, there are many limitations in the current assays of reward deficits in 117 
animal models. For example, the direct link between sucrose preference and anhedonia has 118 
been questioned over the years [13, 14, 37-40]. While a reduced hedonic reaction to sucrose 119 
would be expected to lower sucrose preference, it should also be noted that general 120 
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consumption of reward relies highly on being motivated to attain it, and choice tests require 121 
intact cognitive processes to learn where the rewarding solution is. Thus, it cannot be 122 
concluded that differences in overall consumption of sucrose or sucrose preference 123 
specifically reflect hedonic deficits alone. This highlights the importance of improving current 124 
assays of depressive-like phenotypes such that they specifically measure the symptoms they 125 
are claimed to, and can therefore be used to parse differences in the underlying 126 
neurobiological mechanisms of this complex psychiatric disorder. 127 
It can be difficult to reliably separate reward-related deficits given their interactions, and 128 
measurements of anhedonia in rodent models are often focused on consummatory 129 
behaviours, which may not capture the possibility that patients also experience anticipatory 130 
anhedonia [41, 42]. However, recent developments in our work investigating affective biases 131 
in putative models of depression has revealed some interesting and novel behavioural 132 
differences which could provide new insights into these questions.  133 
In this review, we aim to highlight the importance of modelling symptoms of MDD with more 134 
sensitive behavioural assays in rodent. We will summarise findings in conventional models as 135 
well as discussing new developments in relation to affective biases and reward processing 136 
including potential neurobiological underpinnings of reward processing deficits relevant to 137 
symptoms of MDD. As affective biases are a key symptom of MDD and novel, translatable 138 
methods have recently begun to be described, this review will focus on these recent 139 
developments, as well as how these biases may be dissociable from, but also interact with, 140 
other reward-related deficits. 141 
2. Affective biases in MDD 142 
Impairments in cognitive processes such as executive function, attention, learning and 143 
memory and decision-making have been shown to be core features in patients with MDD [43]. 144 
Such impairments can be separated based on whether they involve dysfunctional processing 145 
of emotional information (“hot”), for example faces displaying different emotional 146 
expressions, or dysfunctional processing of information without emotional influences 147 
(“cold”), for example verbal learning (see Roiser & Sahakian 2013 for a full review [44]). 148 
Patients with MDD show significant impairments in the processing of both “hot” and “cold” 149 
stimuli, with some “cold” processing deficits proposed to result from negative emotions 150 
developed from feedback in the tasks [44]. This concept of “hot” stimuli processing can also 151 
be applied to reward-related stimuli, given that rewards have emotional value [4].  152 
Early theories of cognitive dysfunction in MDD note that negative stimuli and events are more 153 
salient to patients compared to healthy individuals, attributed to a negative self-schema 154 
caused by past experiences, which can lead to biases in processing their environment [45]. 155 
These ‘cognitive’ biases can influence learning and memory, for example, patients often 156 
demonstrate increased recall of negative stimuli compared to positive stimuli [46], and learn 157 
to assign negative connotations to ambiguous stimuli, whilst healthy individuals would show 158 
more positive associations [47, 48]. This processing bias induces negative expectations of 159 
future events, and can alter other cognitive domains  such as decision making and judgement 160 
[49, 50]. In addition to enhanced negative processing biases, patients with MDD show 161 
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reduced biases toward positively valenced stimuli including reduced recognition or 162 
interpretation of positive emotions, decreased memory for positively associated words and 163 
blunted responses to rewards [51, 52]. Studies have also shown that acute antidepressant 164 
treatment can enhance positive biases in healthy volunteers and patients with MDD [53-55]. 165 
For a more detailed discussion of the proposed relationship between affective biases and 166 
mood disorders, and the neuropsychological hypothesis of antidepressant action see Harmer, 167 
Duman and Cowen 2017 [56]. 168 
A task frequently used to specifically measure reward processing biases in humans is the 169 
‘Response Bias Probabilistic Reward Task’ [57]. Here, subjects are presented with two 170 
ambiguous stimuli to which they must discriminatively respond to gain a reward. The correct 171 
identification of one stimulus is more frequently rewarded, so the expected response of 172 
healthy subjects would be to develop a bias for responding to the more frequently rewarded 173 
stimulus, thus demonstrating intact learning and decision-making about reward-related 174 
stimuli. Patients with MDD consistently show an impaired response bias to the more 175 
frequently rewarded cue when the reward is not present, compared to healthy controls [58-176 
61]. This suggests depressed patients have impaired learning and decision-making biases for 177 
“hot” stimuli, i.e. stimuli with emotional value. 178 
More recent theories of these deficits have argued that emotional processing biases are not 179 
solely a result of negative past experiences, but are also driven by aberrant neurobiological 180 
mechanisms. Such mechanisms are thought to involve environmental and/or genetic factors 181 
altering the normal transmission of monoamines [4], which have long been hypothesised to 182 
play a role in depression [62]. This dysfunctional monoamine transmission may then induce 183 
negatively biased expectations, and so it has been suggested these play a causal role in the 184 
development and treatment of depressive symptoms [63, 64].  185 
Evidence for this latter theory comes from studies demonstrating that emotion and reward 186 
processing biases are present in individuals at risk of depression, but not yet demonstrating 187 
other symptoms [65-67], as well as patients in remission [68]. Some studies have also shown 188 
that negative processing biases can predict future diagnoses of MDD [69-71], and can be 189 
correlated with measures of anhedonia [58], whilst the presence of depression in other 190 
disorders has been associated with deficits in reward learning biases [72]. Finally, 191 
monoaminergic antidepressants are shown to reduce negative and induce positive affective 192 
biases prior to changes in mood [64, 73], suggesting affective states influenced by monoamine 193 
transmission works in a bottom-up approach to alter processing of rewarding stimuli leading 194 
to mood changes [74]. 195 
These findings may indeed suggest a relationship between affective biases and the 196 
development of other symptoms of depression. However, as mentioned previously, the 197 
symptomology of MDD is highly heterogeneous, and some evidence suggesting negative 198 
biases can be ameliorated through specifically treating other symptoms of depression [75]. 199 
2.1. Relationship between affective biases and other reward-related deficits 200 
For the purposes of this review, reward-related deficits are categorised in to three 201 
mechanisms of processing involving hedonic responses (‘liking’), motivation (‘wanting’), and 202 
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learning (including anticipation of reward and decision-making capability) [76]. A lack of 203 
consistent evidence for the traditional view of consummatory anhedonia in MDD patients has 204 
led to a re-conceptualization of the term ‘anhedonia’ to refer to an “impaired ability to 205 
pursue, experience and/or learn about pleasure” [77], suggesting anhedonia is not a deficit 206 
only in ‘liking’ but additionally encompasses ‘wanting’ and learning. Although the recognition 207 
of heterogeneity in patients indicates anhedonia might seem to include these three aspects, 208 
but they may not be seen all at the same time, nor all within the same individual.  209 
Evidence suggests these three aspects are inter-related. As mentioned previously, affective 210 
biases are argued to precede other symptoms of MDD including anhedonia and motivational 211 
deficits. In contrast, formal psychological models of learning suggest that reward value 212 
determines the degree and strength of learning about reward [78]. Thus, an under-valuation 213 
of reward, perhaps by reduced hedonic experience, could impair learning about affective 214 
stimuli. Similarly, motivationally-relevant cues for rewards are shown to modulate cognitive 215 
processes such as attention in healthy mice, but not transgenic schizophrenia models [79]. 216 
Thus, even though affective bias may influence other symptoms in some cases, the interaction 217 
between hedonic experience, motivation, and learning may be multifaceted. 218 
Although there are potential interactions between reward-related deficits, it is unlikely that 219 
they can be reduced to any single cause or set of causes. Patient symptoms are highly 220 
heterogeneous; there can be elements of reward processing which are intact whilst other 221 
aspects are dysfunctional. In animal models, combining behavioural assessments of individual 222 
aspects has identified dissociations between the presence of anhedonia and negative 223 
affective bias following pro-depressant treatments [80]. Models of schizophrenia have also 224 
been shown to display reduced positive bias for a greater reward value [81], whilst other 225 
studies show they do not show anhedonia-like deficits [82]. In addition, pharmacological 226 
agents have been identified as specific to influencing either ‘wanting’ or ‘liking’ separately, or 227 
in opposite directions [83]. This indicates mechanisms underlying hedonic experience, 228 
motivation and learning can be separated, implying that – while they may interact – reward-229 
processing deficits are not monolithic, and each needs to be investigated individually.  230 
3. Reward-related deficits in rodents 231 
A major aim for developing tests that can dissociate different symptoms of clinical depression 232 
in animal models is to apply them to understanding the neurobiological mechanisms 233 
underpinning these symptoms and elucidate the causes behind this disorder. Initial theories 234 
of the neurobiological underpinnings of MDD suggest symptoms are caused by a deficiency 235 
in monoamine levels or neurotransmission in the central nervous system, mainly evidenced 236 
by understanding the mechanisms of antidepressants [84]. However, the low success rate in 237 
treating MDD has led to developments of more recent theories which encompass a range of 238 
potential causal mechanisms, such as stress-induced neurotrophic deficits [85, 86] and 239 
aberrant glutamatergic and GABAergic transmission [87]. There are also several different risk 240 
factors which contribute to the development of MDD, suggesting a number of possible 241 
biological and genetic causes of the disorder [14].  242 
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In the following sections, we discuss three major types of reward-related deficit and the 243 
behavioural assays used to measure these deficits in both patients and rodent models of 244 
MDD.  Given the relationship observed between affective biases and reward-related learning, 245 
memory and decision-making, these are discussed within section 3.1. We describe our current 246 
understanding of the neurobiological substrates that might be underpinning these behaviours 247 
from using pharmacological and psychological manipulations, with the aim of elucidating 248 
where distinct or interacting, neurobiological mechanisms contributing to these reward-249 
related deficits. 250 
3.1. Reward learning 251 
Given that impairments in different cognitive domains are a major component of MDD in 252 
patients, it is unsurprising that many assays have been developed to capture these 253 
impairments in rodents. Rodents where a disease model is induced using manipulations based 254 
on relevant risk factors have been shown to develop impairments in multiple types of learning 255 
and memory, ranging from working memory to associative learning (see [88]) with examples 256 
summarised separately below.   257 
3.1.1. Associative learning 258 
Pavlovian associations between a neutral stimulus and an unconditioned stimulus (i.e. 259 
reward) are well known to be formed with repeated pairings [89], and can be strengthened 260 
with greater reward value or altering expectation of reward through prediction error [78]. 261 
Instrumental associations are formed between a neutral stimulus requiring a response to 262 
produce a reward [90]. Dysfunctional associative learning has been linked to the development 263 
of depression, with patients often demonstrating impairments in positive reward associations 264 
[91].  265 
Instrumental learning for reward-related stimuli in rodents typically involve tasks of lever 266 
pressing or nose poking to trigger the release of a reward. In one study, rats were trained to 267 
press a lever for delivery of a sucrose solution. Healthy rats produce progressively more lever 268 
presses as the number of training days increase, indicating they are learning the stimulus-269 
response association, and rodent models of depression have been shown to display a 270 
reduced/slower improvement  [92]. 271 
Many Pavlovian associative learning tasks in rodents involve fear conditioning, for example, 272 
Darcet et al [93] trained mice to associate being placed in a conditioning chamber once with 273 
a foot shock. Models of depression such as the chronic corticosterone model display reduced 274 
freezing time when re-introduced in to the chamber, suggesting reduced fear conditioning 275 
strength. However, since reward-related deficits are a core component of depression 276 
symptoms, reward-related associative learning tasks have also been developed.  277 
In similar, contextual Pavlovian association tasks, Papp et al [12] demonstrated that healthy 278 
rodents show a greater preference for the environment in which several types of rewards 279 
were presented to them, indicating a learned conditioned place preference (CPP). However, 280 
models of chronic unpredictable stress showed reduced CPP, indicating they had reduced 281 
Pavlovian associative learning of reward-related contextual environments.  282 
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Xu et al [94] trained rats to enter a magazine for a sucrose reward, then paired the presence 283 
of a blue light with the delivery of this reward (stimulus-outcome association). They found 284 
that the chronic corticosterone rat model of depression did not demonstrate an increased 285 
number of magazine entries as would be expected with improved learning compared to 286 
controls, indicating that some models of depression display impaired reward-related 287 
associative learning. 288 
3.1.2. Rodent behavioural assays of affective bias 289 
The influence of emotional cues on cognitive function is a major area of depression research 290 
[95] and the reward neuro-circuitry has been heavily linked to disrupted cognition in MDD 291 
[96]. Thus, changes in processing of rewarding stimuli is an important aspect to investigate 292 
when assessing rodent models. 293 
As mentioned previously, the Response-Bias Probabilistic Reward Task (PRT) is used in patient 294 
populations to assess biases in reward processing, and as a result of this a translational 295 
method for rodent models has been developed [97]. Rats were trained to discriminate 296 
between two auditory stimuli, each of which would require a specific operant response to 297 
gain a reward. They were then presented with similar tones, and correct discriminative 298 
responses to one tone would be reinforced with a reward more frequently than correct 299 
responses to the other tone. Like in patient studies, healthy rats develop response biases 300 
toward the stimulus more frequently rewarded, indicating a clear positive response bias.  301 
Alternatively, the probabilistic reversal learning task (PRL) has also been developed, which 302 
assesses alterations in decision-making to positive and negative feedback, enabling detection 303 
of changes in reward sensitivity [98]. In this task, rats are trained to nose poke in an 304 
illuminated hole for a reward, and then presented with two illuminated holes in which one 305 
was more frequently reinforced. The two holes’ probability of reward was then reversed 306 
following eight consecutive correct choices in the more frequently rewarded hole. In a 307 
validation experiment, it was shown that altering serotonin levels differentially influenced the 308 
ability to shift decision-making following reversal (i.e. cognitive flexibility), win-stay behaviour 309 
(i.e. reward sensitivity) and lose-shift behaviour (i.e. negative feedback sensitivity). These 310 
findings are similar to observations in healthy humans [99], and sensitivity to negative 311 
feedback is enhanced in depressed patients [100]. 312 
Emotional decision-making biases in humans can be measured by the affective Go/No-Go 313 
task, where subjects are presented with positive or negative stimuli, e.g. images, to which 314 
they are required to respond. They are also required to withhold responding to distractor 315 
stimuli. Depressed patients display attentional biases for negative stimuli in this task [101], 316 
and also tend to show a bias toward withholding responses with negative outcomes [102]. 317 
Decision making and interpretation biases induced by affective biases in rodents can be 318 
measured by the judgement bias task (JBT) [103]. Rodents are trained to produce one 319 
response to the presentation of a positive stimulus, and a different response to the 320 
presentation of a negative or less positive stimulus. Rodents hypothesised to have a positive 321 
affective state display a bias whereby ambiguous stimuli are more likely to elicit the response 322 
trained to the positive stimulus. In contrast, rodents in a negative affective state exposed to 323 
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the same ambiguous stimuli display a bias to responses trained to the negative stimulus [104-324 
107]. Thus, their judgements and/or interpretations of stimuli can be altered by changes to 325 
their affective states. A novel version of this task has also been developed which utilizes 326 
rodent natural investigative behaviours rather than lever pressing, which recapitulate similar 327 
effects of affective state manipulations on judgement bias [108]. Further, recent studies have 328 
evaluated translational human versions of this task, which link negative biases with 329 
pathological anxiety [95, 109, 110]. 330 
More recently, the affective bias test (ABT) has been developed to address the gap in 331 
assessing learning and memory impairments driven by affective biases (for full reviews of the 332 
ABT see [4, 10, 74]). In this task, rodents associate a particular digging substrate with a reward 333 
and a different substrate with no reward (figure 1a). Rodents hypothesised to have a 334 
pharmacologically induced positive affective state during the presentation of one reward-335 
paired substrate will demonstrate a bias toward that substrate in a choice test with a different 336 
reward-paired substrate in which their affective state was not manipulated (neutral). In 337 
contrast, rodents in a negative affective state will show bias toward the neutral reward-paired 338 
substrate. [80, 111]. Thus, biases in reward-related learning and memory can be influenced 339 
by affective states and such biases can be modelled in rodents.  340 
This task has also been modified to investigate the effects of long-term affective state 341 
manipulations, for example chronic drug treatments or environmental stressors on reward 342 
learning and the ability of an animal to develop a bias towards a cue previously associated 343 
with a higher value reward. In the modified ABT (mABT, figure 1b), rodents are given pairing 344 
sessions to learn the association between one digging substrate and a high value reward (i.e. 345 
two reward pellets), and another digging substrate with a low value reward (i.e. one reward 346 
pellet). A healthy animal develops a bias toward the substrate associated with the higher 347 
valued reward when presented with a choice between the two previously paired substrates, 348 
i.e. a reward-induced positive bias. In contrast, rodents in a putative negative affective state 349 
display no or reduced bias for the higher valued reward [80]. Thus indicating that a negative 350 
affective state can alter reward-related learning and memory. Important for this discussion, 351 
these same animals did not show consistent impairments in SPT or PR tasks suggesting this 352 
reward-learning deficit is not mediated by the same underlying neurobiology as reward 353 
consumption and motivation, and does not result from a change in either of these aspects of 354 
reward processing [80]. 355 
10 
 
Some theories of associative learning suggest it is an automatic, mechanistic process which 356 
does not involve higher-order cognition, although it is argued that this is true for smaller 357 
animals like rodents but human learning involves more complex expectancies of reward [112]. 358 
The loss of reward-induced positive bias that is observed in the mABT could reflect deficits in 359 
expectancies and anticipation of reward, given that this task requires animals to use more 360 
complex cognitive processes involving recalling prior experiences of reward-related stimuli, 361 
modulate decision making and stimulate a directed behaviour [80].  362 
3.1.3. Neurobiological substrates of affective bias 363 
In humans, reductions in monoamines including serotonin, dopamine and noradrenaline have 364 
been linked to impaired reward learning [113], and negative processing biases of rewarding 365 
stimuli [114-118], whilst serotonergic receptor antagonists negatively shift affective 366 
processing biases [119]. In remitted MDD patients, depletions in monoamines can trigger 367 
symptom relapse and changes in emotional processing [120, 121] without directly influencing 368 
mood [122], suggesting this generates a potential vulnerability for developing depressive 369 
symptoms. This is in line with theories of affective bias preceding changes in mood. 370 
   Day 1                    Day 2                   Day 3                   Day 4                            Day 5 
 A
+ 
Drug  Drug  Vehicle  Vehicle  
Preference 
test 
a 
Figure 1. Method overview of the original affective bias test (ABT, a) and the modified ABT (mABT, b).  
In the ABT, rodents undergo four pairing sessions of an affective state-manipulating drug with one type of 
digging substrate (A) or a vehicle with another type (B). A+ and B+ are both rewarded with one reward pellet, 
but are presented alongside a ‘blank’ substrate with no reward (C-). On a preference test day, they are given 
the choice between A or B to investigate with random reinforcement. If their affective state at the time of 
learning about A was positive, they display a preference for A, and vice versa show a bias for B if their 
affective state was negative at the time of learning about A.  
In the mABT, rodents undergo a chronic affective state manipulation via drug treatment or environmental 
factors, then are given four pairing sessions with one digging substrate containing two reward pellets (A++) 
or another substrate containing one reward pellet (B+), each presented alongside C-. Rodents with a neutral 
affective state display a preference for A during the choice test compared to B. If the chronic manipulation 
is proposed to induce a positive affective state, this preference for A will increase, whilst if the manipulation 
is proposed to induce a negative affective state, rodents will show reduced or no preference for A. 
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C- C- C- B+ A A+ B 
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In rodents, pharmacological manipulations have been used to identify potential 371 
neurochemical factors and neurobiological pathways in affective processing biases (see table 372 
2 for a list of example evidence, for a detailed review see [74]). Taking the main affective bias 373 
assays in turn, administration of D2/D3 agonists expected to decrease dopamine signalling 374 
are shown to impair reward bias in rats using the PRT described in 3.2.2 [97], which matches 375 
findings in humans using the original task [123]. Psychosocial stress also impairs reward bias 376 
in both species with the PRT [124, 125]. 377 
Using the JBT, the number of studies investigating neurobiological mechanisms are still 378 
limited but do suggest involvement of monoamines (dopamine and 5-HT, although data for 379 
5-HT is mixed and may depend on acute versus chronic treatment) and the endocannabinoid 380 
system in inducing positive interpretation biases [126, 127]. The benzodiazepine inverse 381 
agonist and, interestingly, noradrenaline re-uptake inhibitors induce a negative bias following 382 
acute treatment [127]. Further, psychosocial stress induces negative interpretation biases 383 
[107] whilst environmental enrichment enhances positive biases [128]. 384 
Negative learning and memory biases have been found in the ABT with acute antagonism of 385 
the endocannabinoid system, along with psychosocial stress, whilst drugs of abuse do not 386 
influence biases [111], indicating the affective state manipulation drives altered learning and 387 
memory bias, not simply activation of the dopamine reward system. Monoamine depletors, 388 
such as tetrabenazine, and several immunomodulators are also shown to induce negative 389 
biases in the ABT [80]. Furthermore, chronic treatment with interferon-alpha (IFN-α) or 390 
retinoic acid reduced reward-induced positive biases in the mABT compared to vehicle 391 
treated controls, whereas consummatory behaviour in the SPT was unaffected by these 392 
treatments [80]. IFN-α is used to treated viral diseases, such as hepatitis C, and has been 393 
associated with the development of depressive symptoms in patients receiving this treatment 394 
[129]. Similarly to findings in the ABT, hepatitis C patients receiving this treatment present 395 
negative biases in processing of emotional facial expressions, though these biases did not 396 
correlate with depression ratings [130]. 397 
Taken together, these current findings suggest that affective biases in learning and memory 398 
are influenced by several biological pathways including altered monoamine transmission, 399 
immunomodulators and stress. Findings in the ABT and JBT using conventional and rapid-400 
onset antidepressants (discussed in section 4) suggest that the formation of affective biases 401 
may be mediated by the amygdala region, while recall of these biases are mediated through 402 
higher cortical and hippocampal regions [106, 131]. These regions can then input to the limbic 403 
reward pathway suggested to play a role in other reward-related behaviours [132, 133]. 404 
Neurobiological studies have linked the amygdala to the formation of an affective bias and 405 
the medial prefrontal cortex linked to recall of this bias [131]. Comparison with other reward 406 
behaviour assays, such as the SPT, suggest the neurobiological mechanisms underpinning 407 
affective biases are, in some cases, separate from other reward-related deficits such as 408 
consummatory anhedonia. 409 
3.2. Hedonic experience 410 
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There are three main domains of reward-related impairments observed in MDD patients. 411 
Deficits in the consummatory hedonic experience derived from rewards, or consummatory 412 
anhedonia, are most often measured in animal models, in contrast to anticipatory anhedonia. 413 
3.2.1. Rodent behavioural assays of consummatory anhedonia 414 
As mentioned previously, the most common method claimed to assess consummatory 415 
anhedonia-like behaviour in rodents is the sucrose preference test (SPT) [35], however there 416 
are several limitations with using this test to isolate anhedonia from other reward-related 417 
deficits, discussed in section 1 of this review.  In patients the ‘sweet taste test’ (STT) has been 418 
used to assess consummatory anhedonia, whereby they are given varying concentrations of 419 
sweet solutions and rate their pleasantness/liking on a self-report scale [134]. Although 420 
anhedonia is repeatedly reported in patients with MDD, self-reported hedonic experience to 421 
sweet solutions appears unaltered [135, 136], which could suggest measuring consumption 422 
of sweet solutions is additionally not an accurate measure of anhedonia in patients. However, 423 
it could also be argued that subjective self-report measurements are not reliable methods to 424 
assay this symptom of MDD. Further, knowing that patients with MDD are highly 425 
heterogeneous in which symptoms they present, more sensitive methods that can reliably 426 
isolate consummatory anhedonia from other reward-related deficits are needed. 427 
To address some issues with measuring consummatory anhedonia, more selective methods 428 
have been developed (for more detailed reviews see [13, 137]). One emphasised by Berridge 429 
and colleagues assesses the natural orofacial reactions to the taste of rewarding or 430 
unpleasant solutions. Rodents display certain categorical facial expressions when tasting 431 
pleasant or unpleasant solutions, and the frequency of these reactions can reflect hedonic 432 
experience and thus are used in studying the neurobiological mechanisms underpinning the 433 
hedonic processing of reward [138].  434 
Another selective measure of objective consummatory behaviour can be taken from the 435 
microstructure of licking. Rodents drink in bouts consisting of multiple licks separated from 436 
other bouts by longer pauses, and the average number of licks within these bouts (lick cluster 437 
size, LCS) has a positive monotonic relationship with increasing concentrations of sucrose, 438 
independent of changes in consumption [139]. This LCS measurement is reduced by 439 
sensations of pain or nausea [140, 141], and our group have also shown this can be reduced 440 
in a chronic corticosterone models of depression (Unpublished; [142]), thus suggesting licking 441 
microstructure can be influenced by negative events and could be used to assay anhedonia-442 
like phenotypes in rodents. 443 
Although these methods of assessing consummatory anhedonia in rodents has been refined 444 
and optimised, and orofacial reactivity has been compared to similar facial expressions 445 
produced by new born infants, it is still open to question how translatable these are to patient 446 
symptomology. As discussed previously, there is little evidence showing blunted or altered 447 
taste reactivity to sweet tastes in depression [135, 143]. Instead, impaired consummatory 448 
anhedonia has been found following self-reported pleasure ratings [144, 145], alongside 449 
deficits in anticipatory anhedonia. This apparent difference could reflect a number of factors, 450 
including difficulties in objectively measuring consummatory behaviour in humans whose 451 
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patterns of eating/drinking are presumably more complex than that of rodents, or that the 452 
majority of human studies use more monetary rewards than the natural rewards of food and 453 
water [41]. Nevertheless, reduced LCS and reduced orofacial reactions to sucrose solutions in 454 
rodents represent a functional analogue of anhedonia (i.e. a reduced response to normatively 455 
rewarding events), regardless of the subjective experience itself [13]. That said, it is important 456 
to acknowledge that these simple measures of consummatory behaviour may not reflect the 457 
complexity of hedonic experience in humans. 458 
3.2.2. Neurobiological substrates of anhedonia 459 
Traditional views of the neuropharmacology of anhedonia in MDD suggested that dopamine 460 
was a core mediator of this reward process, given evidence that dopaminergic receptor 461 
antagonists appeared to inhibit ICSS and CPP learning [146, 147], as well as reducing sucrose 462 
preference in the SPT [148]. More recently, the application of more sensitive analyses of 463 
hedonic experience suggest that consummatory anhedonia is not influenced by dopaminergic 464 
neurotransmission. Instead, these earlier assessments of ‘anhedonia’ did not appropriately 465 
dissociate motivational processes from ‘liking’, and dopamine plays a greater role in incentive 466 
salience than hedonic experience of reward [149-151]. While dopaminergic manipulations 467 
can influence selective consumption-based assays of hedonic responses - for example, Peciña 468 
et al [152] report taste reactivity responses to be influenced by the administration of 469 
dopamine antagonists – the effects are seen either after multiple sessions or late in extended 470 
test sessions. This implies the effects of dopamine on hedonic reactions is indirect and may 471 
rely on interactions with other reward processing aspects, such as learning [13]. 472 
Furthermore, some studies investigating alteration of serotonergic neurotransmission have 473 
also found no effect on lick cluster size (LCS), though inhibition does appear to reduce overall 474 
consumption whilst activation enhances consumption [153, 154]. However, Galistu et al [155] 475 
demonstrate that the atypical antipsychotic Clozapine does increase LCS without influencing 476 
overall consumption. Since Clozapine is believed to work through multiple neurotransmitter 477 
pathways including serotonin and dopamine it could be suggested that some monoaminergic 478 
transmission is involved in hedonic experience, however, their discussion of findings 479 
compared to previous research has ruled out the possibility of 5-HT2 receptors and dopamine 480 
involvement in this process from clozapine’s multiple potential mechanistic actions.  481 
Opioid receptor stimulation in the nucleus accumbens (NAc) and ventral pallidum (VP) 482 
increase positive hedonic orofacial reactions to reward [156, 157]. Lick microstructural 483 
analysis has been less consistent in reporting opioid contribution to hedonic experience, with 484 
many studies showing direct stimulation with opioid agonists/antagonists does not affect LCS 485 
[158, 159]. Based on the evidence in orofacial reactivity studies, it is suggested there are 486 
different ‘hotspots’ in the brains reward system that mediate different aspects of reward 487 
processing. As such, opioid stimulation in specific regions such as the rostrodorsal NAc shell 488 
enhance hedonic reactions to reward [160], whilst in different regions opioid stimulation 489 
enhances motivation/incentive salience [161, 162], which could explain contradictory findings 490 
with less specific opioid stimulation.  491 
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Benzodiazepines, GABAA receptor agonists, have additionally shown to increase orofacial 492 
reactions to rewarding solutions, without affecting aversive reactions to a bitter solution 493 
[163]. Increased LCS following benzodiazepine administration has also been shown using lick 494 
microstructure analysis [164]. Evidence that blocking opioid receptors can attenuate the 495 
effects of benzodiazepines on hedonic reactions suggests the mechanisms by which 496 
benzodiazepines work in hedonic experience may involve opioid neurotransmission [165] 497 
Recent studies in our group have shown distinct effects on hedonic responses following 498 
treatment with IFN-α and corticosterone, both known to induce negative affective biases in 499 
the ABT (Unpublished work; [142]). We found that chronic IFN-α treatment did not affect LCS 500 
in rats using microstructural analysis of licking, supporting findings from previous SPT data 501 
[80, 166]. IFN-α also does not alter the rate of sucrose pellet self-administration [167] or brain 502 
stimulation reward thresholds [168], suggesting its effects on depressive symptoms are not 503 
related to hedonic experience or sucrose preference.  504 
We did find that chronic corticosterone treatment significantly reduced LCS in rats, supporting 505 
previous SPT data [169-171]. Further, psychosocial stress has consistently resulted in reduced 506 
reward sensitivity as indicated by the SPT [12, 35, 172], but there has been very limited 507 
investigation of psychosocial stress with more selective measures of hedonic experience 508 
(although see [13]). 509 
These findings suggest that consummatory hedonic experience can be influenced by limited 510 
neurobiological mechanisms, which include stress and opioid transmission, but potentially 511 
does not directly involve immunomodulatory cytokines or monoaminergic 512 
neurotransmission. However, many of these studies investigate the pharmacological actions 513 
on general hedonic experience, but not in the alleviation of impairments, thus it cannot be 514 
firmly concluded what interaction these neurobiological substrates have on hedonic 515 
experience without more in-depth investigation. 516 
3.3. Motivation 517 
A third major component of reward processing deficits in depressed patients involves 518 
motivation for reward. For many years motivational processes and hedonic experience have 519 
been confounded when assessing clinical populations, potentially contributing to the 520 
difficulty in assessing consummatory anhedonia, as typical self-report measures would not 521 
adequately separate ‘wanting’ from deficits in ‘liking’ [83]. Motivational processes integrate 522 
the biological need for a reward, and learning and memory of a reward-associated stimulus 523 
to drive goal-directed actions to gain the reward [173].  524 
3.3.1. Rodent behavioural assays of motivational deficits 525 
One rodent assay that has been used for several decades to investigate the neurobiological 526 
basis of anhedonia is intracranial self-stimulation (ICSS) [174]. Electrodes are surgically 527 
implanted in specific regions of the limbic system, such as the ventral tegmental area (VTA), 528 
such that activation of the area was achieved by the rodent self-stimulating the electrodes 529 
through responding on a manipulandum. Levels of anhedonia would be scored through 530 
altering the reward stimulation frequency and assessing how much rodents would respond 531 
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to higher or lower frequencies. Models of anhedonia were suggested to show reduced 532 
responding to lower frequencies compared to healthy rodents, and the major neurobiological 533 
pathway thought to be involved in mediating ICSS were dopaminergic [175-177]. However, 534 
this task is now more associated with motivational processing, rather than hedonic 535 
experience [14, 178, 179], through measuring willingness to work for a reward. It could also 536 
be argued that changes in responding to reward frequencies may reflect alterations in motor 537 
activity, especially given dopamine’s role in motor function [180], however, the discrete-trial 538 
current threshold version of the ICSS task has been developed to reduce the sensitivity of this 539 
task to motor impairments [176, 181]. 540 
Another commonly used method for examining motivation for reward in rodents is the 541 
progressive ratio (PR) task, in which the number of lever presses required to obtain a fixed 542 
reward progressively increases, and motivation is assessed as their ‘breakpoint’, i.e. at what 543 
level of effort required will they stop responding [182]. Humans with motivational deficits 544 
show dysfunctional dopaminergic transmission [183, 184] and similarly, disrupted 545 
dopaminergic systems in rodent models impairs motivation in the progressive ratio task [182, 546 
185, 186] suggesting translational neurobiological mechanisms underpinning behaviours in 547 
the PR task. However, in animal models of depression or schizophrenia there has been a lack 548 
of consistent deficits observed in PR tasks [187-189]. There are several limitations of using PR 549 
tasks to represent motivational deficits (see [190]) including difficulty in dissociating between 550 
motivational or motor impairments, whilst some might also argue PR tasks could be 551 
influenced by habitual responding or impulse control deficits [185]. See Salamone [184, 191] 552 
for detailed discussions of a behavioural economics approach suggested to overcome some 553 
of these limitations with PR tasks, which is beyond the scope of this review. 554 
Reward motivation deficits are common in patients with MDD [178, 192] and translational 555 
behavioural assays for these impairments have been developed for humans and animal 556 
models. In patients, methods such as the computer game-based ‘Effort Expenditure for 557 
Rewards Task’ (EEfRT) [193] have been employed to measure such motivational impairments. 558 
Here, subjects have a choice between participating in a low difficulty task (requiring 30 button 559 
presses in 7 seconds) for a smaller monetary reward or a higher difficulty task (requiring 100 560 
button presses in 21 seconds) for a greater monetary reward, thus subjects are required to 561 
use a greater amount of effort to gain a higher value reward. Some studies using this task 562 
have shown a decreased amount of effort expenditure to gain the higher valued reward in 563 
both healthy people with higher ratings of anhedonia [42, 193] and with clinical MDD [194, 564 
195], and some evidence suggests these impairments in the EEfRT are predicted by greater 565 
levels of anticipatory anhedonia [42, 196].  566 
The effort-related choice paradigm task is directly comparable to the EEfRT, in which rodents 567 
are given a choice between pressing a lever several times (most commonly a fixed ratio 5 568 
schedule) to gain one high value reward, or easily accessing low value lab chow from a bowl 569 
in the operant chamber [197]. Thus, like the EEfRT, they are required to produce a greater 570 
amount of effort to gain a higher value reward, and effort-related choice tasks can assess 571 
alterations in motivation for reward as well as decision-making behaviours.   572 
3.3.2. Neurobiological substrates of motivational deficits 573 
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As mentioned previously, motivation and effort have become increasingly recognised as a 574 
process requiring an intact dopaminergic system (see [198-200] for detailed reviews). 575 
Dopamine antagonists and agonists are widely reported to reduce or increase instrumental 576 
responding for rewards respectively [197, 198, 201]. Studies have also shown that levels of 577 
dopamine neurons in the ventrolateral striatum following neurotoxic ablation with 6-578 
hydroxydopamine positively correlated with number of lever press responses in an operant 579 
task [201], indicating dopamine transmission in the reward pathway plays a role in mediating 580 
incentive instrumental responding. Though, there is some contrasting evidence suggesting a 581 
lack of instrumental response changes following acute dopamine antagonist treatment, but 582 
rather dopaminergic signalling influenced Pavlovian reward learning [202]. 583 
The progressive ratio task can be interpreted as measuring the amount of effort rodents are 584 
willing to put in to gain a reward, indicating their level of incentive motivation for such 585 
rewards. This task has thus been used to further indicate involvement of dopamine in 586 
maintaining a high effort for gaining reward [186], as well as opioids [203]. Both dopamine 587 
and opioid treatment have additionally shown to increase incentive salience for Pavlovian 588 
associated reward cues, indicating they are involved in multiple types of associative 589 
motivation for reward [132].  590 
More in-depth investigations of dopamine’s role in motivational processing demonstrate that 591 
manipulators do not affect general food consumption, and in the effort-related choice task, 592 
antagonist-treated rodents will demonstrate greater preference for freely available chow 593 
than the reward requiring operant response [182, 197]. This suggests dopamine mainly 594 
interacts with the instrumental response requirement, that is, initiating and maintaining 595 
effort for retrieving reward, rather than appetite [204]. Studies in psychiatric patients for 596 
whom amotivation is a common symptom support these findings using an effort-based 597 
reinforcement task, demonstrating a correlation between behaviour in this task and striato-598 
orbitofrontal connectivity which is predominantly a dopaminergic pathway [205].  599 
Similar findings to dopamine antagonism in the effort-related choice paradigm have been 600 
shown with agonists of adenosine A2A receptors in the NAc [206, 207], which are believed to 601 
interact with dopamine and dopaminergic receptors in the neostriatal region. Muscarinic 602 
acetylcholine receptor agonists too suppress effortful behaviour for reward and enhance easy 603 
access chow consumption when administered to the NAc core only [208]. Injections of GABAA 604 
receptor agonists in the VP reproduce this low-effort effect in an FR5 vs chow protocol [209], 605 
yet when injected to the NAc shell these agonists have no effect on progressive ratio 606 
behaviour [203].  607 
Alternately, serotonergic pathways do not appear to play a role in effort-choice/motivational 608 
processes. Denk et al demonstrated that treatment with a tryptophan hydroxylase inhibitor 609 
did not affect performance of rats in a T-maze task given a choice between climbing a barrier 610 
to gain a high valued reward or entering an obstacle-free arm to gain a low reward, whereas 611 
those treated with a dopamine receptor antagonist showed reduced effort [210]. Similarly, 612 
Izquierdo et al reproduced this lack of effect of the tryptophan hydroxylase inhibitor on the 613 
same task, but found that instead rats showed an impaired reversal learning, suggesting the 614 
serotonergic system may be more involved in cognitive reward processing [211]. However, it 615 
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has been shown that an antagonist for serotonin 2C receptors can enhance instrumental 616 
responding in a progressive ratio task and increase effort for greater reward in the effort-617 
related choice paradigm [212]. Given that antagonism of these receptors increase 618 
dopaminergic firing from the ventral tegmental area and NAc, it is thought that this underlying 619 
mechanism involves dopamine signalling more than serotonin itself. 620 
These recent developments in uncovering the psychopharmacology of effort-related choice 621 
behaviour highlight a specific network of neurotransmitters that interact and target NAc and 622 
VP regions to regulate motivational processing of reward.  623 
3.4. Summary 624 
The challenge of reliably measuring and dissociating reward processing deficits has been 625 
highlighted through inconsistencies in reporting and treating patient symptoms. Assays often 626 
used in patients do not effectively differentiate between multiple reward-related 627 
components that may be disrupted, and as a result, treatments have had poor efficacy. 628 
Developments in rodent assays of reward-related deficits are beginning to reveal dissociable 629 
behaviours specifically linked to separate domains of reward processing. Important to this 630 
discussion is data for the same manipulations inducing dissociable effects on different 631 
measures of reward, as illustrated in figure 2. Here, and in Stuart et al [80], chronic 632 
pharmacological treatments were shown to induce a deficit in reward-induced positive biases 633 
with no effect in the SPT. We have also undertaken a pilot study to investigate reward learning 634 
using a lever press task where chronic IFN-α treatment had no effect, further supporting our 635 
conclusions that the effects seen in the modified ABT are specific.  636 
Findings in these more sensitive pre-clinical behavioural assays have revealed complex 637 
neurobiological pathways that may be involved in reward processing and their associated 638 
deficits in disease. Although hedonic value, motivation and reward-related cognition all 639 
contribute the arising behaviour, animal studies are revealing that important differences 640 
underlie these behaviours. From recent studies, monoaminergic and GABAergic 641 
neurotransmitter pathways have been identified as playing a role in mediating affective 642 
biases and motivational processing, while consummatory hedonic experience appears to be 643 
mediated more by opioid transmission with some overlapping GABAergic effects. Notably, 644 
several forms of stress induction negatively influence all three aspects of reward processing, 645 
whilst immunomodulatory manipulations do not influence current measures of 646 
consummatory anhedonia, but do modify affective biases. Neuro-circuit analyses are also 647 
starting to reveal the distinct neural circuits underlying these behaviours [131].  648 
From the evidence to date, we can support the hypothesis that distinct neurobiological 649 
mechanisms may underpin reward-related learning and memory deficits in models of MDD, 650 
as well as mechanisms involved in incentive motivation arising from the re-activation of 651 
reward-associated memories, compared to hedonic experience [74]. However, there are still 652 
some overlaps and interactions between these processes which indicate they are not entirely 653 
separate, thus, heterogeneity seen in patients may arise from differences in aberrant 654 
neurobiological changes, along with different environmental and genetic factors. Further, 655 
issues with clinical assessments remain, in particular relating to hedonic experience. 656 
Development of human tasks that can similarly dissociate between these different aspects of 657 
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reward processing would be valuable both in terms of understanding the relationship 658 
between these deficits and disease symptoms, but also to enhance the translational validity 659 
of rodent models [178]. 660 
 661 
 662 
 663 
 664 
 665 
 666 
 667 
 668 
 669 
 670 
 671 
 672 
 673 
Figure 2. Specific affective bias deficits with chronic interferon-alpha (IFN-α) treatment.  
Chronic interferon-alpha (IFN-α) treatment induces a deficit in reward-induced positive bias (panel 
A) but has no effect on sucrose preference (panel B).  The data shown in panel A and B are from 
the same animals which received a 14-day treatment with IFN-α (100u/kg, i.p. once daily) or control 
and then tested in the modified affective bias test and a 1% sucrose preference test (data taken 
from Stuart et al., 2017).  In a separate cohort of rats (n=6 per group) a preliminary study using a 
lever press task failed to show any deficit in learning to associated one lever with a higher value 
reward (panel C, data unpublished, Benn et al). In this pilot studies, animals were first trained using 
a continuous reinforcement schedule where each lever was presented on alternate days until they 
were consistently responding with >50 lever presses/session.  Animals were then switched to a 
protocol where both levers were presented and responses paired with either a one or 2 pellet 
reward (left or right lever press was paired with the higher value reward, counter-balanced across 
animals). IFN-α treatment (14 days, once daily, dosing before testing) failed to induce any learning 
deficit with the animals treated with IFN-α showing a higher rate of acquisition (main effect of 
Session F (2.4, 24.1) = 19.95, p <0.001 and Group F (1, 10) = 8.32, p = 0.016 but no Grp*Session F 
(2.4, 24.1) = 0.56, p = 0.607).  Although only a small scale pilot experiment, these data do support 
our hypothesis that the deficits seen in the m-ABT are related to the ability to use reward 
information to guide behaviour when the current information available is ambiguous.  During the 
choice test, rats must rely on their prior knowledge to make a decision about which substrate to 
choose as the reinforcement schedule is randomised for this phase of the task.  In the sucrose 
preference test and lever press task, the information about reward value is available throughout 
the task and animals do not show the same impairment.   
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4. Antidepressant actions and implications for treatments 676 
Current treatments for MDD are limited in their robustness, with one third of patients 677 
remaining unresponsive following several courses of antidepressant and psychological 678 
therapies [217], and current antidepressants have limited impact on reward processing 679 
deficits such as anhedonia [218]. To improve treatment efficacy, valid animal models 680 
appropriately reflecting the behavioural and neurobiological impairments seen in patients are 681 
essential for testing novel therapies. Here, we will discuss some of the current literature 682 
describing potential mechanisms of action of antidepressants, as shown in the more sensitive 683 
behavioural assays discussed previously, and related to our updated knowledge of the 684 
neurobiological substrates underpinning such behaviours. 685 
Aberrant monoamine neurotransmission has been implicated in the development of affective 686 
biases. Typical antidepressants tend to target these systems and have been shown to reverse 687 
negative affective processing biases and enhance positive biases in patients [219], as well as 688 
healthy subjects [55]. Similarly, this has been shown with various atypical antidepressants 689 
that involve some manipulation of monoaminergic pathways [53]. Some of the most 690 
commonly prescribed antidepressants are selective serotonin reuptake inhibitors (SSRIs), 691 
which have been shown to increase reward learning in patients [54]. The effects of 692 
monoamine-targeting antidepressants on other aspects of reward processing deficits is much 693 
less consistent, often having little effect on motivational deficits and anhedonia in MDD 694 
patients [15, 220]. Though, patient studies on antidepressant actions in motivation tasks such 695 
as the EEfRT, along with translational assays of anhedonia, are limited, but recent theories 696 
suggest dopamine-targeting antidepressants should be used in combination with SSRIs to 697 
enhance the motivational deficits of depression [221].  698 
In animal models, studies have shown that reward preference deficits following chronic stress 699 
seen in the SPT can be reversed with typical antidepressant treatments [35, 222, 223], while 700 
there is limited pharmacological evidence for antidepressant effects in the more sensitive 701 
methods of anhedonia discussed previously. Dopamine enhancing drugs not typically 702 
prescribed as antidepressants have shown to reverse amotivational shifts in the effort-related 703 
choice task in rats [224], whilst serotonin-targeting typical antidepressants do not [225], 704 
supporting the specific role of dopamine in motivational processing. However, studies where 705 
tetrabenazine is used to induce a deficit have shown subsequent reversal with 706 
monoaminergic antidepressants [225]. 707 
However, serotonergic modifying antidepressants are shown to enhance positive reward 708 
sensitivity and learning in the PRL task [98]. Various monoaminergic and atypical 709 
antidepressants also enhance positive affective biases in the ABT [80, 111, 226, 227] (see 710 
figure 1 and [74] for a recent overview of antidepressant actions). The recent development of 711 
these tasks mean no studies, to our knowledge, have yet investigated the effects of these 712 
antidepressants on reversing negative depression-like phenotypes induced by known risk 713 
factors.  Thus, more studies are needed to determine whether, and how, these 714 
antidepressants can alleviate negative processing biases induced by negative affective states, 715 
as well as further examinations of how different antidepressants might influence hedonic and 716 
motivational processing. 717 
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Despite this evidence that enhancing monoaminergic transmission may improve affective bias 718 
and dopamine replenishment could improve motivational deficits, the therapeutic effects of 719 
monoaminergic antidepressants take several weeks to become effective, even though 720 
increases in monoamine release can be detected immediately [228]. This observation has led 721 
to potential implications of more prolonged downstream changes in neuroplasticity leading 722 
from these monoamine changes in the efficacy of antidepressants [229].  723 
This theory of the delayed onset action of typical antidepressants has brought about an 724 
abundance of literature in support of neuro-adaptive changes involvement in the 725 
development and treatment of MDD symptoms [230-233]. However, a more recent theory 726 
has been proposed, describing a cognitive neuropsychological mechanism of action for 727 
antidepressants that combines the clinical and preclinical evidence of affective biases in MDD 728 
with this neuroplasticity hypothesis [64]. In this model, antidepressants rapidly induce a 729 
positive shift in the negative processing biases experienced by patients, which is then 730 
gradually expected to improve the impairments in behaviour and mood. Thus, suggesting 731 
positive affective biases may not directly enhance mood and other deficits in MDD but could 732 
provide a cognitive neuropsychological mechanism for this to occur. It also suggests that the 733 
delayed improvement in mood may result from the need for re-learning positive associations 734 
between affective and social stimuli [56]. This would also fit with the evidential link between 735 
neuroplasticity and learning [234], indicating potentially antidepressants improve plasticity 736 
which improves positive affective learning, or it may be that the improved learning through 737 
positive affective biases enhances plasticity as suggested in an alternative hypothesis outlined 738 
by Robinson 2018 [74]. 739 
Some antidepressants, such as the NMDA receptor antagonist ketamine, are shown to have 740 
rapid-onset improvements in MDD patients [235], including in patients shown to be 741 
unresponsive to several courses of typical antidepressant treatments. This is thought to occur 742 
through a more rapid activation of neuroplasticity changes [236, 237]. However, a new 743 
proposal suggests differences in delayed vs rapid onset antidepressants might lie in the way 744 
they influence affective biases [74]. In the ABT, FG7142- and psychosocial stress-induced 745 
negative affective biases in rodent models can be reduced following ketamine treatment, but 746 
not treatment with the delayed onset antidepressant, venlafaxine, whereas ketamine failed 747 
to induce any bias alone [131]. This effect of ketamine was specific to the medial prefrontal 748 
cortex (mPFC), whilst venlafaxine was specific to the amygdala. These findings could suggest 749 
that rapid onset antidepressants act upon previously learned negative biases through changes 750 
in the mPFC to stabilise these biases rapidly, which is separate from delayed onset actions of 751 
initiating new learning of positive biases in other limbic areas [74]. 752 
Recent studies using the JBT have also investigated the effects of ketamine on decision-753 
making biases, demonstrating similar temporal differences between rapid-onset and 754 
conventional antidepressants in inducing positive biases as seen in clinical populations, as 755 
well as indicating the involvement of distinct neurobiological substrates underlying these 756 
differences (for a more detailed discussion see Hales et al [106]). However, there are still 757 
patients for which these antidepressants do not work at all and are possibly resistant to the 758 
neuropsychological changes mentioned here. A potential hypothesis for treatment-resistant 759 
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patients is that these patients may have poorer social support and continuous negative 760 
environmental interactions that dampen the improvements in affective biases through 761 
pharmacological treatment alone [56]. This could lead to failure to re-engage with social 762 
and/or rewarding activities that is essential for re-learning positive experiences.  763 
Thus, the cognitive neuropsychological model for MDD suggests taking more integrated 764 
approaches in investigating the underlying causes, as well as treatment, of MDD, and 765 
potential differences in the neurobiological and behavioural mechanisms of distinct 766 
symptoms suggest that understanding this complex disorder should involve combining 767 
assessments of different aspects that are impaired. 768 
5. Conclusion 769 
Although hedonic value, motivation and reward-related cognition all contribute to reward 770 
processing and associated reward-related deficits, important differences underlie these 771 
behaviours. Biases in the processing of reward-related information, including biases in 772 
learning and memory and decision-making, have been observed in humans and, more 773 
recently, in rodents. These behaviours are not directly related to the more typical measures 774 
of reward, and add another dimension to the discussions relating to how reward-related 775 
behaviours may be altered in diseases such as MDD. In this review, we show that commonly 776 
impaired aspects of reward processing could have some distinct neurobiological 777 
underpinnings. We emphasise the importance of investigating different reward-related 778 
deficits separately, and potentially combining several sensitive behavioural methods in 779 
clinical and preclinical research, to thoroughly identify neurobiological targets of individual 780 
symptoms of MDD, in order to improve the development and evaluation of novel therapies.  781 
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